Trials / Completed
CompletedNCT03550378
A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well Tolerated
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MEDI0382 in Subjects With Type 2 Diabetes Mellitus and Renal Impairment
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- MedImmune LLC · Industry
- Sex
- All
- Age
- 18 Years – 84 Years
- Healthy volunteers
- Not accepted
Summary
A study to look at the effect MEDI0382 has on blood sugar in people with type 2 diabetes and kidney problems and also to check that MEDI0382 is well tolerated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MEDI0382 | Participants will receive subcutaneous MEDI0382 titrated from 50 μg upto 300 μg (50 μg once daily for 4 days, followed by 100 μg daily for 7 days, 200 μg daily for 7 days, and 300 μg daily for 14 days) for 32 days. |
| DRUG | Placebo | Participants will receive SC placebo matched to MEDI0382 once daily for 32 days. |
Timeline
- Start date
- 2018-06-29
- Primary completion
- 2019-02-04
- Completion
- 2019-02-04
- First posted
- 2018-06-08
- Last updated
- 2020-04-13
- Results posted
- 2020-04-13
Locations
7 sites across 2 countries: Germany, United Kingdom
Source: ClinicalTrials.gov record NCT03550378. Inclusion in this directory is not an endorsement.